Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.43 |
| ▸ | CA7 | P43166 | 7/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124063 | 0.84 | CA1 (0.39) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738104 | 0.84 | GRM7 (0.40) | CA1CA2CA12CA7CA14 | |
| SCHEMBL21810781 | 0.82 | MTNR1A (0.48) | — | |
| SCHEMBL21810779 | 0.82 | MTNR1A (0.48) | — | |
| SCHEMBL7248144 | 0.80 | CA1 (0.43) | CA1CA2CA12CA7CA14 | |
| SCHEMBL7690123 | 0.80 | CA1 (0.43) | CA1CA2CA12CA7CA14 | |
| SCHEMBL4607688 | 0.79 | MAPT (0.45) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3441786 | 0.78 | CA1 (0.43) | CA1CA2CA12CA7CA14 | |
| SCHEMBL29189280 | 0.77 | CA1 (0.53) | CA1CA2CA12CA7CA14 | |
| SCHEMBL2283276 | 0.77 | MAPT (0.50) | GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487781-B1 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | NOVARTIS AG (CH) | 2008-07-23 | — | — | EP | claimed |
| CN-1268605-C | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | claimed |
| US-6933410-B2 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | claimed |
| CN-1639111-A | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | claimed |
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2003-10-02 | — | — | US | claimed |
| EP-1487781-B1 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | NOVARTIS AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1487781-B1 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | NOVARTIS AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| CN-1268605-C | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| US-6933410-B2 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | disclosed |
| CN-1639111-A | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NAT1, AADAC, IDH3A | CA1 2153/4885CA2 1591/4885CA12 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.